N. Ait-daoud, B. A. Johnson, M. Javors, J. D. Roache, and N. A. Zanca, Combining Ondansetron and Naltrexone Treats Biological Alcoholics: Corroboration of Self-Reported Drinking by Serum Carbohydrate Deficient Transferrin, A Biomarker, Alcoholism: Clinical and Experimental Research, vol.37, issue.6, pp.847-849, 2001.
DOI : 10.1093/alcalc/34.5.760

N. Ait-daoud, B. A. Johnson, T. J. Prihoda, and I. D. Hargita, Combining ondansetron and naltrexone reduces craving among biologically predisposed alcoholics: preliminary clinical evidence, Psychopharmacology, vol.154, issue.1, pp.23-27, 2001.
DOI : 10.1007/s002130000607

S. M. Angelone, L. Bellini, D. Bella, D. Catalano, and M. , EFFECTS OF FLUVOXAMINE AND CITALOPRAM IN MAINTAINING ABSTINENCE IN A SAMPLE OF ITALIAN DETOXIFIED ALCOHOLICS, Alcohol and Alcoholism, vol.33, issue.2, pp.151-156, 1998.
DOI : 10.1093/oxfordjournals.alcalc.a008371

R. F. Anton, D. J. Drobes, K. Voronin, R. Durazo-avizu, and D. Moak, Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking, Psychopharmacology, vol.173, issue.1-2, pp.32-40, 2004.
DOI : 10.1007/s00213-003-1720-7

R. F. Anton, D. H. Moak, and P. H. Latham, The Obsessive Compulsive Drinking Scale, Archives of General Psychiatry, vol.53, issue.3, pp.225-256, 1996.
DOI : 10.1001/archpsyc.1996.01830030047008

R. F. Anton, H. Pettinati, A. Zweben, H. R. Kranzler, B. Johnson et al., A Multi-site Dose Ranging Study of Nalmefene in the Treatment of Alcohol Dependence, Journal of Clinical Psychopharmacology, vol.24, issue.4, pp.421-428, 2004.
DOI : 10.1097/01.jcp.0000130555.63254.73

B. Bencherif, G. S. Wand, M. E. Mccaul, Y. K. Kim, N. Ilgin et al., Muopioid receptor binding measured by [11C] carfentanil positron emission tomography is related to craving and mood in alcohol dependence, Biological Psychiatry, issue.3, pp.55-255, 2004.

U. Berggren, M. Eriksson, C. Fahlke, and J. Balldin, Relationship between central serotonergic neurotransmission and reduction in alcohol intake by citalopram, Drug and Alcohol Dependence, vol.63, issue.3, pp.263-267, 2001.
DOI : 10.1016/S0376-8716(00)00218-0

J. Besson, F. Aeby, A. Kasas, P. Lehert, and A. Potgieter, Combined Efficacy of Acamprosate and Disulfiram in the Treatment of Alcoholism, Alcoholism: Clinical & Experimental Research, vol.22, issue.3, pp.573-579, 1998.
DOI : 10.1097/00000374-199805000-00004

D. F. Braus, J. Wrase, S. Grusser, D. Hermann, M. Ruf et al., Alcohol-associated stimuli activate the ventral striatum in abstinent alcoholics, Journal of Neural Transmission, vol.108, issue.7, pp.887-894, 2001.
DOI : 10.1007/s007020170038

E. S. Brown, L. Bobadilla, V. A. Nejtek, D. Perantie, H. Dhillon et al., Open-label nefazodone in patients with a major depressive episode and alcohol dependence, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.27, issue.4, pp.681-685, 2003.
DOI : 10.1016/S0278-5846(03)00079-4

B. Carmen, M. Angeles, M. Ana, and A. J. Maria, Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review, Addiction, vol.140, issue.7, pp.99-811, 2004.
DOI : 10.1111/j.1360-0443.2004.00763.x

J. Chick, H. Aschauer, K. Hornik, and . Investigators-'group, Efficacy of fluvoxamine in preventing relapse in alcohol dependence: a one-year, double-blind, placebo-controlled multicentre study with analysis by typology, Drug and Alcohol Dependence, vol.74, issue.1, pp.61-70, 2004.
DOI : 10.1016/j.drugalcdep.2003.11.012

J. Chick, H. Howlett, M. Y. Morgan, and B. Ritson, UNITED KINGDOM MULTICENTRE ACAMPROSATE STUDY (UKMAS): A 6-MONTH PROSPECTIVE STUDY OF ACAMPROSATE VERSUS PLACEBO IN PREVENTING RELAPSE AFTER WITHDRAWAL FROM ALCOHOL, Alcohol and Alcoholism, vol.35, issue.2, pp.176-187, 2000.
DOI : 10.1093/alcalc/35.2.176

C. R. Cloninger, Tridimensional Personality Questionnaire (TPQ) (version 4), 1987.

C. Study and R. Group, Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods. Alcoholism, Clinical and Experimental Research, vol.27, issue.7, pp.1107-1022, 2003.

N. L. Cooney, M. D. Litt, P. A. Morse, L. O. Bauer, and L. Gaupp, Alcohol cue reactivity, negative-mood reactivity, and relapse in treated alcoholic men., Journal of Abnormal Psychology, vol.106, issue.2, pp.243-250, 1997.
DOI : 10.1037/0021-843X.106.2.243

J. R. Cornelius, I. M. Salloum, M. D. Cornelius, J. M. Perel, J. G. Ehler et al., Preliminary report: Double-blind, placebo-controlled study of fluoxetine in depressed alcoholics, Psychopharmacology Bulletin, issue.2, pp.31-297, 1995.

J. R. Cornelius, I. M. Salloum, M. D. Cornelius, J. M. Perel, M. E. Thase et al., Fluoxetine trial in suicidal depressed alcoholics, Psychopharmacology Bulletin, vol.29, issue.2, pp.195-199, 1993.

J. R. Cornelius, I. M. Salloum, J. G. Ehler, P. J. Jarrett, M. D. Cornelius et al., Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial, Archives of General Psychiatry, issue.8, pp.54-700, 1997.

J. R. Cornelius, I. M. Salloum, R. F. Haskett, D. C. Daley, M. D. Cornelius et al., Fluoxetine versus placebo in depressed alcoholics, Addictive Behaviors, vol.25, issue.2, pp.307-310, 2000.
DOI : 10.1016/S0306-4603(99)00065-9

J. R. Cornelius, I. M. Salloum, M. E. Thase, R. F. Haskett, D. C. Daley et al., Fluoxetine versus placebo in depressed alcoholic cocaine abusers, Psychopharmacology Bulletin, vol.34, issue.1, pp.117-121, 1998.

H. Coskunol, O. Goekden, E. S. Ercan, E. Bayraktar, I. Tuglular et al., Long-term efficacy of sertraline in the prevention of alcoholic relapses in alcohol-dependent patients: A single-center, double-blind, randomized, placebo-controlled, parallel-group study, Current Therapeutic Research, vol.63, issue.11, pp.63-759, 2002.
DOI : 10.1016/S0011-393X(02)80096-0

D. Davidson, T. Palfai, C. Bird, and R. Swift, Effects of Naltrexone on Alcohol Self-Administration in Heavy Drinkers, Alcoholism: Clinical and Experimental Research, vol.29, issue.2, pp.195-203, 1999.
DOI : 10.1111/j.1530-0277.1995.tb00988.x

D. Wildt, W. A. Schippers, G. M. Van-den-brink, W. Potgieter, A. S. Deckers et al., DOES PSYCHOSOCIAL TREATMENT ENHANCE THE EFFICACY OF ACAMPROSATE IN PATIENTS WITH ALCOHOL PROBLEMS?, Alcohol and Alcoholism, vol.37, issue.4, pp.375-382, 2002.
DOI : 10.1093/alcalc/37.4.375

D. J. Drobes, R. F. Anton, S. E. Thomas, and K. Voronin, A Clinical Laboratory Paradigm for Evaluating Medication Effects on Alcohol Consumption: Naltrexone and Nalmefene, Neuropsychopharmacology, vol.28, issue.4, pp.755-764, 2003.
DOI : 10.1038/sj.npp.1300101

D. J. Drobes, R. F. Anton, S. E. Thomas, and K. Voronin, Effects of Naltrexone and Nalmefene on Subjective Response to Alcohol Among Non-Treatment-Seeking Alcoholics and Social Drinkers, Alcoholism: Clinical & Experimental Research, vol.54, issue.9, pp.1362-1370, 2004.
DOI : 10.1016/S0741-8329(99)00006-3

M. Eriksson, U. Berggren, K. Blennow, C. Fahlke, and J. Balldin, Further investigation of citalopram on alcohol consumption in heavy drinkers: responsiveness possibly linked to the DRD2 A2/A2 genotype, Alcohol, vol.24, issue.1, pp.15-23, 2001.
DOI : 10.1016/S0741-8329(01)00137-9

P. J. Geerlings, C. Ansoms, and W. Van-den-brink, Acamprosate and Prevention of Relapse in Alcoholics, European Addiction Research, vol.3, issue.3, pp.129-137, 1997.
DOI : 10.1159/000259166

G. Gerra, R. Caccavari, R. Delsignore, R. Bocchi, G. Fertonani et al., Effects of fluoxetine and ca-acetyl-homotaurinate on alcohol intake in familial and nonfamilial alcoholic patients, Current Therapeutic Research, vol.52, issue.2, pp.291-295, 1992.
DOI : 10.1016/S0011-393X(05)80480-1

H. Gottesman and T. D. Gould, The Endophenotype Concept in Psychiatry: Etymology and Strategic Intentions, American Journal of Psychiatry, vol.160, issue.4, pp.636-645, 2003.
DOI : 10.1176/appi.ajp.160.4.636

R. A. Greenstein, B. D. Evans, A. T. Mclellan, and C. P. O-'brien, Predictors of favorable outcome following naltrexone treatment, Drug and Alcohol Dependence, vol.12, issue.2, pp.173-180, 1983.
DOI : 10.1016/0376-8716(83)90042-X

P. Heinala, H. Alho, K. Kiianmaa, J. Lonnqvist, K. Kuoppasalmi et al., Targeted Use of Naltrexone Without Prior Detoxification in the Treatment of Alcohol Dependence: A Factorial Double-Blind, Placebo-Controlled Trial, Journal of Clinical Psychopharmacology, vol.21, issue.3, pp.287-292, 2001.
DOI : 10.1097/00004714-200106000-00006

A. Heinz, S. Lö-ber, A. Georgi, J. Wrase, D. Hermann et al., REWARD CRAVING AND WITHDRAWAL RELIEF CRAVING: ASSESSMENT OF DIFFERENT MOTIVATIONAL PATHWAYS TO ALCOHOL INTAKE, Alcohol and Alcoholism, vol.38, issue.1, pp.35-39, 2003.
DOI : 10.1093/alcalc/agg005

A. Heinz, P. Ragan, D. W. Jones, D. Hommer, W. Williams et al., Reduced Central Serotonin Transporters in Alcoholism, American Journal of Psychiatry, vol.155, issue.11, pp.155-1544, 1998.
DOI : 10.1176/ajp.155.11.1544

C. A. Hernandez-avila, V. Modesto-lowe, R. Feinn, and H. R. Kranzler, Nefazodone Treatment of Comorbid Alcohol Dependence and Major Depression, Alcoholism: Clinical & Experimental Research, vol.54, issue.3, pp.433-440, 2004.
DOI : 10.1016/0002-9343(83)90349-2

D. Hersh, J. R. Van-kirk, and H. R. Kranzler, Naltrexone treatment of comorbid alcohol and cocaine use disorders, Psychopharmacology, vol.139, issue.1-2, pp.44-52, 1998.
DOI : 10.1007/s002130050688

V. Hesselbrock, H. Begleiter, B. Porjesz, S. O-'connor, and L. Bauer, P300 event-related potential amplitude as an endophenotype of alcoholism ??? Evidence from the collaborative study on the genetics of alcoholism, Journal of Biomedical Science, vol.65, issue.suppl, pp.77-82, 2001.
DOI : 10.1007/BF02255974

W. G. Iacono, S. R. Carlson, and S. M. Malone, Identifying a multivariate endophenotype for substance use disorders using psychophysiological measures, International Journal of Psychophysiology, vol.38, issue.1, pp.81-96, 2000.
DOI : 10.1016/S0167-8760(00)00132-X

A. J. Jaffe, B. Rounsaville, G. Chang, R. S. Schottenfeld, R. E. Meyer et al., Naltrexone, relapse prevention, and supportive therapy with alcoholics: An analysis of patient treatment matching., Journal of Consulting and Clinical Psychology, vol.64, issue.5, pp.1044-1053, 1996.
DOI : 10.1037/0022-006X.64.5.1044

L. Janiri, G. Gobbi, P. Mannelli, and G. Pozzi, Effects of fluoxetine and antidepressant doses on shortterm outcome of detoxified alcoholics, International Clinical Psychopharmacology, vol.11, issue.2, pp.109-117, 1996.

B. A. Johnson, Serotonergic agents and alcoholism treatment: Rebirth of the subtype concept ? a hypothesis. Alcoholism, Clinical and Experimental Research, vol.24, issue.10, pp.1597-1601, 2000.

B. Johnson, N. Ait-daoud, and K. Lawson, Dual biomarkers corroborate efficacy of combining ondansetron and naltrexone for the treatment of biological alcoholism, European Neuropsychopharmacology, pp.12-400, 2002.

B. A. Johnson, N. Ait-daoud, J. Z. Ma, and Y. Wang, Ondansetron reduces mood disturbances among biologically predisposed, alcohol-dependent individuals. Alcoholism, Clinical and Experimental Research, issue.11, pp.27-1773, 2003.

B. A. Johnson, N. Ait-daoud, and T. J. Prihoda, Combining Ondansetron and Naltrexone Effectively Treats Biologically Predisposed Alcoholics: From Hypotheses to Preliminary Clinical Evidence, Alcoholism: Clinical and Experimental Research, vol.49, issue.5, pp.737-742, 2000.
DOI : 10.1007/BF00969884

B. A. Johnson, J. D. Roache, N. Ait-daoud, N. A. Zanca, and M. Velazquez, Ondansetron reduces the craving of biologically predisposed alcoholics, Psychopharmacology, vol.160, issue.4, pp.408-413, 2002.
DOI : 10.1007/s00213-002-1002-9

B. A. Johnson, J. D. Roache, M. A. Javors, C. C. Diclemente, C. R. Cloninger et al., Ondansetron for Reduction of Drinking Among Biologically Predisposed Alcoholic Patients, JAMA, vol.284, issue.8, pp.284-963, 2000.
DOI : 10.1001/jama.284.8.963

D. I. Kabel and F. Petty, A Placebo-Controlled, Double-Blind Study of Fluoxetine in Severe Alcohol Dependence: Adjunctive Pharmacotherapy During and After Inpatient Treatment, Alcoholism: Clinical and Experimental Research, vol.18, issue.4, pp.780-784, 1996.
DOI : 10.1111/j.1360-0443.1995.tb01013.x

F. Kiefer, Combined therapy: what does Campral and Naltrexone combination tell us, Congress presentation on Fifth Annual Meeting of the International Society of Addiction Medicine (ISAM), 2003.

F. Kiefer, F. Andersohn, H. Jahn, K. Wolf, T. J. Raedler et al., Involvement of plasma atrial natriuretic peptide in protracted alcohol withdrawal, Acta Psychiatrica Scandinavica, vol.294, issue.1, pp.65-70, 2002.
DOI : 10.1016/0014-2999(86)90570-4

F. Kiefer, H. Jahn, M. Jaschinski, R. Holzbach, K. Wolf et al., Leptin: A modulator of craving?, Biological Psychiatry, issue.9, pp.49-782, 2001.

F. Kiefer, H. Jahn, T. Tarnaske, H. Helwig, P. Briken et al., Comparing and Combining Naltrexone and Acamprosate in Relapse Prevention of Alcoholism, Archives of General Psychiatry, vol.60, issue.1, pp.92-99, 2003.
DOI : 10.1001/archpsyc.60.1.92

A. C. King, J. Schluger, M. Gunduz, L. Borg, G. Perret et al., Hypothalamicpituitary-adrenocortical (HPA) axis response and biotransformation of oral naltrexone: Preliminary examination of relationship to family history of alcoholism, Neuropsychopharmacology, issue.6, pp.26-778, 2002.

A. C. King, J. R. Volpicelli, A. Frazer, and C. P. O-'brien, Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence, Psychopharmacology, vol.129, issue.1, pp.15-22, 1997.
DOI : 10.1007/s002130050156

H. R. Kranzler, Evaluation and treatment of anxiety symptoms and disorders in alcoholics, Journal of Clinical Psychiatry, vol.57, pp.15-21, 1996.

H. R. Kranzler and J. Van-kirk, Efficacy of Naltrexone and Acamprosate for Alcoholism Treatment: A Meta-Analysis, Alcoholism: Clinical and Experimental Research, vol.54, issue.9, pp.1335-1341, 2001.
DOI : 10.1016/S0140-6736(96)91682-7

H. R. Kranzler, J. A. Burleson, J. Brown, and T. F. Babor, Fluoxetine Treatment Seems to Reduce the Beneficial Effects of Cognitive-Behavioral Therapy in Type B Alcoholics, Alcoholism: Clinical and Experimental Research, vol.21, issue.Suppl., pp.1534-1541, 1996.
DOI : 10.1111/j.1530-0277.1996.tb01696.x

H. R. Kranzler, A. Pierucci-lagha, R. Feinn, and C. Hernandez-avila, Effects of Ondansetron in Early- Versus Late-Onset Alcoholics: A Prospective, Open-Label Study, Alcoholism: Clinical & Experimental Research, vol.20, issue.7, pp.1150-1155, 2003.
DOI : 10.1016/0014-2999(90)90015-X

O. M. Lesch and H. Walter, SUBTYPES OF ALCOHOLISM AND THEIR ROLE IN THERAPY, Alcohol and Alcoholism, vol.31, issue.supp1, pp.63-67, 1996.
DOI : 10.1093/oxfordjournals.alcalc.a008221

D. Lichtermann, P. Franke, W. Maier, and M. L. Rao, Pharmacogenomics and addiction to opiates, European Journal of Pharmacology, vol.410, issue.2-3, pp.269-279, 2000.
DOI : 10.1016/S0014-2999(00)00820-7

J. Littleton, M. Qatari, and H. Little, The neurobiology of craving: Potential mechanisms for acamprosate Acamprosate in relapse prevention of alcoholism, pp.27-46, 1996.

A. M. Ludwig, A. Wikler, and L. H. Stark, The First Drink, Archives of General Psychiatry, vol.30, issue.4, pp.539-547, 1974.
DOI : 10.1001/archpsyc.1974.01760100093015

T. S. Malec, E. A. Malec, and M. Dongier, Efficacy of Buspirone in Alcohol Dependence: A Review, Alcoholism: Clinical and Experimental Research, vol.15, issue.5, pp.853-858, 1996.
DOI : 10.1111/j.1530-0277.1995.tb01532.x

K. Mann, Pharmacotherapy of Alcohol Dependence, CNS Drugs, vol.340, issue.3, pp.485-504, 2004.
DOI : 10.2165/00023210-200418080-00002
URL : https://hal.archives-ouvertes.fr/hal-01276028

K. Mann, P. Lehert, and M. Y. Morgan, The Efficacy of Acamprosate in the Maintenance of Abstinence in Alcohol-Dependent Individuals: Results of a Meta-Analysis, Alcoholism: Clinical & Experimental Research, vol.21, issue.1, pp.51-63, 2004.
DOI : 10.1016/S0140-6736(96)91682-7

B. J. Mason, E. C. Ritvo, R. O. Morgan, F. R. Salvato, G. Goldberg et al., A Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Efficacy and Safety of Oral Nalmefene HCI for Alcohol Dependence, Alcoholism: Clinical and Experimental Research, vol.33, issue.5, pp.1162-1167, 1994.
DOI : 10.1037//0021-843X.91.3.199

B. J. Mason, F. R. Salvato, L. D. Williams, E. C. Ritvo, and R. B. Cutler, A double-blind, placebocontrolled study of oral nalmefene for alcohol dependence, Archives of General Psychiatry, issue.8, pp.56-719, 1999.

S. Maxwell and M. S. Shinderman, Use of Naltrexone in the Treatment of Alcohol Use Disorders in Patients with Concomitant Major Mental Illness, Journal of Addictive Diseases, vol.39, issue.11, pp.61-69, 2000.
DOI : 10.1300/J069v19n03_05

M. E. Mccaul, G. S. Wand, T. Eissenberg, C. A. Rohde, and L. J. Cheskin, Naltrexone Alters Subjective and Psychomotor Responses to Alcohol in Heavy Drinking Subjects, Neuropsychopharmacology, vol.22, issue.5, pp.22-480, 2000.
DOI : 10.1016/S0893-133X(99)00147-5

E. P. Merikle, The Subjective Experience of Craving: An Exploratory Analysis, Substance Use & Misuse, vol.101, issue.8, pp.1101-1115, 1999.
DOI : 10.1001/archpsyc.1974.01760100093015

D. H. Moak, R. F. Anton, P. K. Latham, K. E. Voronin, R. L. Waid et al., Sertraline and Cognitive Behavioral Therapy for Depressed Alcoholics: Results of A Placebo-Controlled Trial, Journal of Clinical Psychopharmacology, vol.23, issue.6, pp.553-562, 2003.
DOI : 10.1097/01.jcp.0000095346.32154.41

J. R. Monterosso, B. A. Flannery, H. M. Pettinati, D. W. Oslin, M. Rukstalis et al., Predicting treatment response to naltrexone: The influence of craving and family history, J. R. The American Journal on Addictions, vol.10, issue.3, pp.258-268, 2001.

C. A. Naranjo, K. E. Bremner, M. Bazoon, and I. B. Turksen, Using fuzzy logic to predict response to citalopram in alcohol dependence, Clinical Pharmacology & Therapeutics, vol.56, issue.2, pp.209-224, 1997.
DOI : 10.1016/S0009-9236(97)90070-9

C. A. Naranjo, D. M. Knoke, and K. E. Bremner, Variations in response to citalopram in men and women with alcohol dependence, Journal of Psychiatry & Neuroscience, vol.25, issue.3, pp.269-275, 2000.

R. S. Niaura, D. J. Rohsenow, J. A. Binkoff, P. M. Monti, M. Pedraza et al., Relevance of cue reactivity to understanding alcohol and smoking relapse., Journal of Abnormal Psychology, vol.97, issue.2, pp.133-152, 1988.
DOI : 10.1037/0021-843X.97.2.133

O. Malley, S. S. Jaffe, A. J. Chang, G. Rode, R. Schottenfeld et al., Six-Month Follow-up of Naltrexone and Psychotherapy for Alcohol Dependence, Archives of General Psychiatry, vol.53, issue.3, pp.217-224, 1996.
DOI : 10.1001/archpsyc.1996.01830030039007

O. Malley, S. S. Jaffe, A. J. Chang, G. Schottenfeld, R. S. Meyer et al., Naltrexone and coping skills therapy for alcohol dependence. A controlled study, Archives of General Psychiatry, issue.11, pp.49-881, 1992.

O. Malley, S. S. Krishnan-sarin, S. Farren, C. Sinha, R. Kreek et al., Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis, Psychopharmacology, vol.160, issue.1, pp.19-29, 2002.
DOI : 10.1007/s002130100919

D. W. Oslin, W. Berrettini, H. R. Kranzler, H. Pettinati, J. Gelernter et al., A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcoholdependent patients, Neuropsychopharmacology, issue.8, pp.28-1546, 2003.

D. Oslin, J. G. Liberto, J. O-'brien, S. Krois, and J. Norbeck, Naltrexone as an Adjunctive Treatment for Older Patients With Alcohol Dependence, The American Journal of Geriatric Psychiatry, vol.5, issue.4, pp.324-332, 1997.
DOI : 10.1097/00019442-199700540-00007

D. W. Oslin, H. M. Pettinati, J. R. Volpicelli, A. L. Wolf, K. M. Kampman et al., The Effects of Naltrexone on Alcohol and Cocaine Use in Dually Addicted Patients, Journal of Substance Abuse Treatment, vol.16, issue.2, pp.163-167, 1999.
DOI : 10.1016/S0740-5472(98)00039-7

T. Palfai, D. Davidson, and R. Swift, Influence of naltrexone on cue-elicited craving among hazardous drinkers: The moderational role of positive outcome expectancies., Experimental and Clinical Psychopharmacology, vol.7, issue.3, pp.266-273, 1999.
DOI : 10.1037/1064-1297.7.3.266

I. Pelc, C. Ansoms, P. Lehert, F. Fischer, W. J. Fuchs et al., The European NEAT program: an integrated approach using acamprosate and psychosocial support W, 2002.

H. M. Pettinati, W. Dundon, and C. Lipkin, Gender Differences in Response to Sertraline Pharmacotherapy in Type A Alcohol Dependence, American Journal on Addictions, vol.13, issue.3, pp.236-247, 2004.
DOI : 10.1080/10550490490459906

H. M. Pettinati, J. R. Volpicelli, H. R. Kranzler, G. Luck, M. R. Rukstalis et al., Sertraline Treatment for Alcohol Dependence: Interactive Effects of Medication and Alcoholic Subtype, Alcoholism: Clinical and Experimental Research, vol.17, issue.1, pp.1041-109, 2000.
DOI : 10.1007/s002130050962

H. M. Pettinati, J. R. Volpicelli, G. Luck, H. R. Kranzler, M. R. Rukstalis et al., Double-Blind Clinical Trial of Sertraline Treatment for Alcohol Dependence, Journal of Clinical Psychopharmacology, vol.21, issue.2, pp.143-153, 2001.
DOI : 10.1097/00004714-200104000-00005

T. E. Robinson and K. C. Berridge, The neural basis of drug craving: An incentive-sensitization theory of addiction, Brain Research Reviews, vol.18, issue.3, pp.247-291, 1993.
DOI : 10.1016/0165-0173(93)90013-P

D. J. Rohsenow, What Place Does Naltrexone Have in the Treatment of Alcoholism?, CNS Drugs, vol.2, issue.9, pp.547-560, 2004.
DOI : 10.2165/00023210-200418090-00001

P. P. Roy-byrne, K. P. Pages, J. E. Russo, C. Jaffe, A. W. Blume et al., Nefazodone Treatment of Major Depression in Alcohol-Dependent Patients: A Double-Blind, Placebo-Controlled Trial, Journal of Clinical Psychopharmacology, vol.20, issue.2, pp.129-136, 2000.
DOI : 10.1097/00004714-200004000-00003

I. M. Salloum, J. R. Cornelius, M. E. Thase, D. C. Daley, L. Kirisci et al., Naltrexone utility in depressed alcoholics, Psychopharmacology Bulletin, vol.34, issue.1, pp.111-115, 1998.

H. Sass, Results from a pooled analysis of 11 European trials comparing acamprosate and placebo on the treatment of alcohol dependence, Alcohol and Alcoholism, vol.30, p.551, 1995.

H. Sass, M. Soyka, K. Mann, and W. Zieglgänsberger, Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence, Archives of General Psychiatry, issue.8, pp.53-673, 1996.
DOI : 10.1001/archpsyc.1996.01830080023006

E. M. Sellers, T. Toneatto, M. K. Romach, G. R. Somer, L. C. Sobell et al., Clinical Efficacy of the 5-HT3 Antagonist Ondansetron in Alcohol Abuse and Dependence, Alcoholism: Clinical and Experimental Research, vol.18, issue.2, pp.879-885, 1994.
DOI : 10.1007/BF02244425

J. D. Sinclair, Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism, Alcohol and Alcoholism, vol.36, issue.1, pp.2-10, 2001.
DOI : 10.1093/alcalc/36.1.2

T. B. Sloan, J. D. Roache, and B. A. Johnson, THE ROLE OF ANXIETY IN PREDICTING DRINKING BEHAVIOUR, Alcohol and Alcoholism, vol.38, issue.4, pp.360-363, 2003.
DOI : 10.1093/alcalc/agg090

M. Soyka, U. Preuss, and C. Schuetz, Use of Acamprosate and Different Kinds of Psychosocial Support in Relapse Prevention of Alcoholism, Drugs in R & D, vol.58, issue.1, pp.1-12, 2002.
DOI : 10.2165/00126839-200203010-00001

R. Spanagel and W. Zieglgänsberger, Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes, Trends in Pharmacological Sciences, vol.18, issue.2, pp.54-59, 1997.
DOI : 10.1016/S0165-6147(97)89800-8

M. Srisurapanont and N. Jarusuraisin, Opioid antagonists for alcohol dependence. (Cochrane Review) In: The Cochrane Library, Issue 3, 2004.

S. Stoltenberg, Serotonergic Agents and Alcoholism Treatment: A Simulation, Alcoholism: Clinical & Experimental Research, vol.293, issue.12, pp.1853-1859, 2003.
DOI : 10.1016/S0924-977X(99)00057-7

C. Streeton and G. Whelan, NALTREXONE, A RELAPSE PREVENTION MAINTENANCE TREATMENT OF ALCOHOL DEPENDENCE: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS, Alcohol and Alcoholism, vol.36, issue.6, pp.544-552, 2001.
DOI : 10.1093/alcalc/36.6.544

R. M. Swift, Drug therapy for alcohol dependence, The New England Journal of Medicine, vol.340, issue.19, pp.1482-1487, 1999.

S. T. Tiffany, New Perspectives on the Measurement, Manipulation and Meaning of Drug Craving, Human Psychopharmacology: Clinical and Experimental, vol.97, issue.S2, pp.103-113, 1997.
DOI : 10.1002/(SICI)1099-1077(199706)12:2+<S103::AID-HUP907>3.0.CO;2-8

G. D. Tollefson, Anxiety and alcoholism: A serotonin link, The British Journal of Psychiatry, vol.12, pp.34-39, 1991.

G. D. Tollefson, J. Montague-clouse, and S. L. Tollefson, Treatment of Comorbid Generalized Anxiety in a Recently Detoxified Alcoholic Population with a Selective Serotonergic Drug (Buspirone), Journal of Clinical Psychopharmacology, vol.12, issue.1, pp.19-26, 1992.
DOI : 10.1097/00004714-199202000-00004

U. Who, Report: United Nations International Drug Control Programme and World Health Organization technical report series No. V, Informal Expert Committee on the Craving Mechanism, pp.92-54439, 1992.

R. Verheul, P. Lehert, P. J. Geerlings, M. W. Koeter, and W. Van-den-brink, Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients, Psychopharmacology, vol.53, issue.Suppl 20, pp.167-173, 2005.
DOI : 10.1007/s00213-004-1991-7

R. Verheul, W. Van-den-brink, and P. J. Geerlings, A three-pathway psychobiological model of craving for alcohol., Alcohol and Alcoholism, vol.34, issue.2, pp.197-222, 1999.
DOI : 10.1093/alcalc/34.2.197

N. D. Volkow, G. J. Wang, J. S. Fowler, J. Logan, R. Hitzemann et al., Decreases in Dopamine Receptors but not in Dopamine Transporters in Alcoholics, Alcoholism: Clinical and Experimental Research, vol.224, issue.9, pp.1594-1598, 1996.
DOI : 10.1111/j.1530-0277.1996.tb05936.x

J. R. Volpicelli, A. I. Alterman, M. Hayashida, and C. P. O-'brien, Naltrexone in the Treatment of Alcohol Dependence, Archives of General Psychiatry, vol.49, issue.11, pp.49-876, 1992.
DOI : 10.1001/archpsyc.1992.01820110040006

J. R. Volpicelli, K. L. Clay, N. T. Watson, and C. P. O-'brien, Naltrexone in the treatment of alcoholism: predicting response to naltrexone, The Journal of Clinical Psychiatry, issue.7, pp.56-95, 1995.

J. R. Volpicelli, K. C. Rhines, L. A. Volpicelli, A. I. Alterman, and C. P. O-'brien, Naltrexone and alcohol dependence. Role of subject compliance, Archives of General Psychiatry, issue.8, pp.54-737, 1997.

G. S. Wand, D. Mangold, and M. Ali, Adrenocorticotropin responses to naloxone in sons of alcoholdependent men, Journal of Clinical Endocrinology and Metabolism, vol.84, issue.1, pp.64-68, 1999.

G. S. Wand, D. Mangold, S. Deiry, M. E. Mccaul, and D. Hoover, Family History of Alcoholism and Hypothalamic Opioidergic Activity, Archives of General Psychiatry, vol.55, issue.12, pp.55-1114, 1998.
DOI : 10.1001/archpsyc.55.12.1114

G. S. Wand, M. E. Mccaul, D. Gotjen, J. Reynolds, and S. Lee, Confirmation That Offspring From Families With Alcohol-Dependent Individuals Have Greater Hypothalamic-Pituitary-Adrenal Axis Activation Induced by Naloxone Compared With Offspring Without a Family History of Alcohol Dependence, Alcoholism: Clinical and Experimental Research, vol.23, issue.8, pp.25-1134, 2001.
DOI : 10.1016/S0306-4530(00)00021-4

A. B. Whitworth, F. Fischer, O. M. Lesch, A. Nimmerrichter, H. Oberbauer et al., Comparison of acamprosate and placebo in long-term treatment of alcohol dependence, The Lancet, vol.347, issue.9013, pp.347-1438, 1996.
DOI : 10.1016/S0140-6736(96)91682-7

G. Winterer, M. A. Enoch, K. V. White, M. Saylan, R. Coppola et al., EEG phenotype in alcoholism: increased coherence in the depressive subtype, Acta Psychiatrica Scandinavica, vol.10, issue.1, pp.51-60, 2003.
DOI : 10.1016/S0197-0186(00)00054-1

R. A. Wise, The neurobiology of craving: Implications for the understanding and treatment of addiction., Journal of Abnormal Psychology, vol.97, issue.2, pp.118-132, 1988.
DOI : 10.1037/0021-843X.97.2.118